Cognition Therapeutics, Inc. announced that all participants have completed their final clinic visits in the Phase 2 SHIMMER study of CT1812 in patients with mild-to-moderate dementia with Lewy bodies (DLB). This milestone indicates the successful operational conclusion of the trial's patient interaction phase.
The SHIMMER study enrolled 130 adults with mild-to-moderate DLB, who were randomized to receive either placebo or one of two oral once-daily doses of CT1812 for six months. The study aims to assess the tolerability profile and identify signals of efficacy across measures of cognition and function.
The company anticipates that topline results from this study, which investigates CT1812 in a second dementia indication, will be available and reported in December 2024. This sets the stage for a significant data readout that could impact the future development of CT1812 for DLB.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.